复星医药：H股--全球发售公告英文
The information contained herein does not constitute an offer of securities for sale in the United States. Securities may not
be offered or sold in the United States unless they are registered under applicable law or are exempt from registration
under the U.S. Securities Act. No public offer of securities will be made in the United States.
This announcement is for information purposes only and does not constitute an invitation or offer by any person to acquire,
purchase or subscribe for securities. Potential investors should read the prospectus of Shanghai Fosun Pharmaceutical
(Group) Co., Ltd. (the ‘‘Company’’) dated 17 October 2012 (the ‘‘Prospectus’’) for detailed information about the Global
Offering described below before deciding whether or not to invest in the H Shares thereby being offered.
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the ‘‘Hong Kong Stock
Exchange’’) and Hong Kong Securities Clearing Company Limited (the ‘‘HKSCC’’) take no responsibility for the contents of
this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
announcement.
Unless otherwise defined in this announcement, terms defined in the Prospectus have the same meanings when used in this
announcement.
上 海 �� 星 �t �（ 集 �F ）股 份 有 限 公 司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
(a joint stock limited company incorporated in the People’s Republic of China with limited liability)
GLOBAL OFFERING
Number of Offer Shares : 336,070,000 H Shares (subject to the
Over-allotment Option)
Number of Hong Kong Offer Shares : 33,607,000 H Shares (subject to adjustment)
Number of International Offer Shares : 302,463,000 H Shares (subject to adjustment
and the Over-allotment Option)
Maximum Offer Price : HK$13.68 per Offer Share plus brokerage of 1%,
SFC transaction levy of 0.003% and
Hong Kong Stock Exchange trading fee
of 0.005% (payable in full on application,
subject to refund)
Nominal value : RMB1.00 per H Share
Stock code : 02196
Joint Sponsors, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
�C1�C
Application has been made to the Listing Committee of the Hong Kong Stock Exchange for the
granting of the listing of, and permission to deal in, the H Shares to be issued pursuant to the Global
Offering (including any additional H Shares which may be issued by the Company pursuant to the
exercise of the Over-allotment Option). Dealings in the H Shares on the Hong Kong Stock Exchange
are expected to commence at 9:00 a.m. on Tuesday, 30 October 2012. The H Shares will be traded in
board lots of 500 Shares each. In the event the Over-allotment Option is exercised, an announcement
will be made.
Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and
conditions of the Prospectus and the related Application Forms.
Applicants who wish to be allotted the Hong Kong Offer Shares in their own names should (i)
complete and sign the WHITE Application Form; or (ii) submit applications online through the
designated website of the HK eIPO White Form Service Provider at www.hkeipo.hk under the HK
eIPO White Form service. Applicants who wish to have the Hong Kong Offer Shares allotted and
issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their
CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS
Participants should (i) complete and sign the YELLOW Application Forms; or (ii) give electronic
application instructions to HKSCC via CCASS.
Copies of the Prospectus, together with the WHITE Application Forms, may be obtained during
normal business hours from 9:00 a.m. on Wednesday, 17 October 2012 until 12:00 noon on Monday,
22 October 2012 from any of the following addresses:
1. UBS AG, Hong Kong Branch, 52/F, Two International Finance Centre, 8 Finance Street, Central,
Hong Kong;
2. China International Capital Corporation Hong Kong Securities Limited, 29/F, One International
Finance Centre, 1 Harbor View Street, Central, Hong Kong;
3. J.P. Morgan Securities (Asia Pacific) Limited, 28th Floor, Chater House, 8 Connaught Road
Central, Central, Hong Kong;
4. Deutsche Bank AG, Hong Kong Branch, Level 52, International Commerce Centre, 1 Austin Road
West, Kowloon, Hong Kong;
5. Guotai Junan Securities (Hong Kong) Limited, 27th Floor, Low Block, Grand Millennium Plaza,
181 Queens’s Road Central, Central, Hong Kong; or
6. Haitong International Securities Company Limited, 22/F, Li Po Chun Chambers, 189 Des Voeux
Road Central, Hong Kong
�C2�C
or any of the following branches of the receiving banks for the Hong Kong Public Offering:
(a) Bank of Communications Co., Ltd. Hong Kong Branch
Branch Name Address
Hong Kong Island Hong Kong Branch 20 Pedder Street, Central
Chaiwan Sub-Branch G/F., 121�C121A Wan Tsui Road
Wanchai Sub-Branch G/F., 32�C34 Johnston Road
Kowloon Kowloon Sub-Branch G/F., 563 Nathan Road
Ngau Tau Kok Sub-Branch Shop G1 & G2, G/F., Phase I, Amoy
Plaza, 77 Ngau Tau Kok Road
New Territories Tiu Keng Leng Sub-Branch Unit L2-064 & 065, Metro Town
Shopping Mall, 8 King Ling Road
Tai Po Sub-Branch Shop No. 1, G/F., Wing Fai Plaza,
29�C35 Ting Kok Road
Sheung Shui Sub-Branch Shops 10�C14, G/F., Sheung Shui
Centre Shopping Arcade
(b) Standard Chartered Bank (Hong Kong) Limited
Branch Name Address
Hong Kong Island 88 Des Voeux Road Branch 88 Des Voeux Road Central, Central
Hennessy Road Branch 399 Hennessy Road, Wanchai
Quarry Bay Branch G/F, Westlands Gardens, 1027
King’s Road, Quarry Bay
Kowloon Kwun Tong Hoi Yuen Road G/F, Fook Cheong Building, No. 63
Hoi Yuen Road, Kwun Tong,
Kowloon
Tsimshatsui Branch G/F, 8A-10 Granville Road,
Tsimshatsui
Mei Foo Manhattan Branch Shop Nos. 07 & 09, Ground Floor,
Mei Foo Plaza, Mei Foo Sun
Chuen
Metroplaza Branch Shop No. 175�C176, Level 1,
Metroplaza, 223 Hing Fong Road,
Kwai Chung
New Territories Tseung Kwan O Branch Shop G37�C40, G/F, Hau Tak
Shopping Centre East Wing,
Hau Tak Estate, Tseung Kwan O
�C3�C
(c) Wing Lung Bank Limited
Branch Name Address
Hong Kong Island Head Office 45 Des Voeux Road Central
North Point Branch 361 King’s Road
Kowloon Mongkok Branch B/F Wing Lung Bank Centre,
636 Nathan Road
Sham Shui Po Branch 111 Tai Po Road
To Kwa Wan Branch 64 To Kwa Wan Road
New Territories Shatin Plaza Branch 21 Shatin Centre Street
Tsuen Wan Branch 251 Sha Tsui Road
Yuen Long Branch 37 On Ning Road
Copies of the Prospectus, together with the YELLOW Application Forms, may be obtained during
normal business hours from 9:00 a.m. on Wednesday, 17 October 2012 until 12:00 noon on Monday,
22 October 2012 at the Depository Counter of HKSCC at 2nd Floor, Infinitus Plaza, 199 Des Voeux
Road Central, Hong Kong or your stockbroker, who may have YELLOW Application Forms and
Prospectus available.
Applicants applying by HK eIPO White Form may submit application to the designated HK eIPO
White Form Service Provider through the designated website www.hkeipo.hk from 9:00 a.m. on
Wednesday, 17 October 2012 until 11:30 a.m. on Monday, 22 October 2012 or such later time as
described under the section headed “How to Apply for the Hong Kong Offer Shares ― Effect of Bad
Weather on the Opening of the Application Lists” in the Prospectus (24 hours daily, except on the last
application day).
CCASS Investor Participant can input electronic application instructions from 9:00 a.m. on
Wednesday, 17 October 2012 until 12:00 noon on Monday, 22 October 2012.
Please refer to the “Structure of the Global Offering” and “How to Apply for the Hong Kong Offer
Shares” sections of the Prospectus for details of the conditions and procedures of the Hong Kong
Public Offering.
�C4�C
The Company expects to announce the Offer Price, the level of applications in the Hong Kong Public
Offering, the level of indications of interest in the International Offer and the basis of allocation of
Hong Kong Offer Shares will be made available on the websites of the Hong Kong Stock Exchange at
www.hkexnews.hk and the Company at www.fosunpharma.com on Monday, 29 October 2012. The
results of allocations and the Hong Kong Identity Card/passport/Hong Kong Business Registration
Certificate numbers of successful applicants under the Hong Kong Public Offering will be available in
a manner described in the section headed ‘‘How to Apply for Hong Kong Offer Shares ― X. Results of
Allocations’’ in the Prospectus).
The Company will not issue any temporary documents of title. No receipt will be issued for application
monies paid. The H Shares will be traded in board lots of 500 each under the stock code 02196.
Dealings in the H Shares on the Hong Kong Stock Exchange are expected to commence at 9:00 a.m.
on Tuesday, 30 October 2012.
By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Chen Qiyu
Chairman
Hong Kong, 17 October 2012
As of the date of this announcement, the executive Directors of the Company are Mr. Chen Qiyu (Chairman) and Mr. Yao
Fang; the non-executive Directors are Mr. Guo Guangchang, Mr. Wang Qunbin and Mr. Zhang Guozheng; the independent
non-executive Directors are Mr. Guan Yimin, Mr. Han Jiong and Dr. Zhang Weijiong.
Please also refer to the published version of this announcement in the South China Morning Post (in English) and the Hong
Kong Economic Times (in Chinese).
* For identification purpose only
�C5�C
相关阅读：
验证码：
- 最新评论
- 我的评论